Amgen Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Operating-Income" stands at 8.66 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 12/31/2023.
Amgen Inc's third quarter result of 2.53 Billion USD for the item "Operating Income" represents a decrease of -4.46 percent compared to it's second quarter result.
Also, Amgen Inc's third quarter result of 2.53 Billion USD for the item "Operating Income" represents an increase of 23.40 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Amgen Inc's third quarter result of 8.66 Billion USD for the item "Operating Income" represents an increase of 5.86 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 39.26 percent compared to the value the year prior.
The 1 year change in percent is 39.26.
The 3 year change in percent is -10.18.
The 5 year change in percent is -5.67.
The 10 year change in percent is 9.66.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Operating Income | 905,699,262,464.00 |
![]() | Johnson & Johnson - Operating Income | 486,508,953,600.00 |
![]() | AbbVie Inc - Operating Income | 399,570,305,024.00 |
![]() | Roche Holding AG - Operating Income | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Operating Income | 280,205,508,085.11 |